Mainz Biomed Set to Showcase Industry-Leading Outcomes: 100% Sensitivity and 95% Specificity
BERKELEY, Calif., February 24, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic firm focused on early cancer detection, is pleased to announce its involvement in the prestigious Digestive Disease Week (DDW) 2026, held in Chicago, Illinois. During the event, the company will display its poster entitled “BLOOD-BASED mRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DIFFERENTIATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS”.
“We are delighted with the team’s advancements in validating the robust clinical findings from our discovery research. What’s especially noteworthy is that our algorithm and biomarker selection can detect neoplasms in blood samples. Offering a blood-based test that can identify early-stage disease marks a significant step toward the early detection—and eventual eradication—of pancreatic cancer,” stated Guido Baechler, CEO of Mainz Biomed
Follow us to remain informed:
About Mainz Biomed NV
Mainz Biomed creates market-ready molecular genetic diagnostic tools for life-threatening illnesses. The company’s product pipeline centers on PancAlert, an early-stage pancreatic cancer screening test that uses real-time Polymerase Chain Reaction (PCR)-based multiplex detection of molecular-genetic biomarkers in blood and stool samples. For more information, visit or follow us on , and .
For investor inquiries, please reach out to
Forward-Looking Statements
Certain statements contained in this press release qualify as “forward-looking statements” under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be recognized by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” along with other similar phrases that forecast or point to future events or trends, or that do not relate to historical facts. These forward-looking statements are based on the current analysis of available data and are subject to a range of risks and uncertainties. Therefore, care should be taken when relying on these forward-looking statements. Because of both known and unknown risks, actual outcomes may vary significantly from the company’s expectations or forecasts. Several factors, including but not limited to the following, could lead to material differences between actual results and those outlined in these forward-looking statements: (i) failing to achieve projected development and related goals; (ii) shifts in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the company and its current or target markets; and (iv) other risks and uncertainties mentioned in this release, as well as those discussed periodically in other reports and public filings the company submits to the Securities and Exchange Commission (the “SEC”). Further details about these and other factors that may affect the company’s expectations and projections are available in its initial SEC filings, including its Form 20-F annual report filed on March 31, 2025 and its Form 6-K mid-year report filed on September 26, 2025. The company’s SEC filings are publicly accessible on the SEC’s website at www.sec.gov. Any forward-looking statement in this press release is based solely on information available to Mainz Biomed at the time of writing and is only valid as of that date. Mainz Biomed does not assume any obligation to publicly update any forward-looking statement—whether written or oral—that may be issued from time to time, whether due to new information, future developments, or other reasons, unless required by law.
